Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin injections in age-related macular degeneration
2007-003766-17Phase 2Completed
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in age-related macular degeneration (AMD), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoints: Visual acuity change at 6 months and Visual acuity change at 1 year. Started Jul 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2007-003766-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003766-17.